Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing. Cell Q™ addresses a critical challenge.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, it has launched Fosaprepitant for Injection and Fulvestrant Injection in the United States.
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
Organon & Co. Samsung Bioepis Co., Ltd. that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States.
Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Fluphenazine Hydrochloride Tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths.